USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
Intek Diagnostics Inc.
Address:
1450 Rollins Road
Burlingame, CA 94010
Phone:
N/A
URL:
N/A
EIN:
N/A
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $250,000.00 5
SBIR Phase II $126,000.00 1

Award List:

THERE ARE NO SENSITIVE METHODS FOR THE DIAGNOSIS OF METASTASES AND LYMPH NODE INVOLVEMENT IN HUMAN SQUAMOUS CELL CARCINOMA (SCC) OF THE HEAD AND NECK REGION.

Award Year / Program / Phase:
1985 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Toby gottfried , PRINCIPAL INVESTIGATOR
Abstract:
There are no sensitive methods for the diagnosis of metastases and lymph node involvement in human squamous cell carcinoma (scc) of the head and neck region. radioimmunodetection is capable of high resolution and sensitivity in locating tumors. the long-term goal of this research proposal is the… More

INTEK DIAGNOSTICS, INC.

Award Year / Program / Phase:
1985 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Ray ranken , PRINCIPAL INVESTIGATOR
Abstract:
Intek diagnostics, inc. (formerly carcinex, inc.) is a small business corporation funded to develop and market new methods to diagnose, stage, and treat squamous cell carcinomas. intek diagnostics has developed a library of highly tumor-associated murine monoclonal antibodies. these antibodies react… More

INTEK HAS DEVELOPED OVER 20 VERY PROMISING TUMOR-ASSOCIATED AND POSSIBLY TUMOR-SPECIFIC MURINE MONOCLONAL ANTIBODIES AGAINST SQUAMOUS CELL CARCINOMA (SCC) TUMORS.

Award Year / Program / Phase:
1985 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Ronald jones , PRINCIPAL INVESTIGATOR
Abstract:
Intek has developed over 20 very promising tumor-associated and possibly tumor-specific murine monoclonal antibodies against squamous cell carcinoma (scc) tumors. there are currently no immunological methods in use for monitoring scc patients for recurrence of tumor, or for identification of… More

METHODS ARE NOW AVAILABLE FOR IDENTIFYING AND PURIFYING A VAST ARRAY OF ANTIGENS EXPRESSED ON TUMOR CELLS.

Award Year / Program / Phase:
1985 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Patricia a. nelson , PRINCIPAL INVESTIGATOR
Abstract:
Methods are now available for identifying and purifying a vast array of antigens expressed on tumor cells. the purpose of the proposed studies is to develop methods for sensitizing t cells to antigens that can be purified from tumor cell membranes, rather than sensitizing with intact tumor cells… More

IMMUNOHISTOCHEMICAL STUDY OF ORAL DYSPLASIA AND CARCINOMA

Award Year / Program / Phase:
1986 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Raymond Ranken , Principal Investigator
Abstract:
N/a

IMMUNOHISTOCHEMICAL STUDY OF ORAL DYSPLASIA AND CARCINOMA

Award Year / Program / Phase:
1987 / SBIR / Phase II
Award Amount:
$126,000.00
Agency:
HHS
Principal Investigator:
Raymond Ranken , Principal Investigator
Abstract:
There are no sensitive in vitro diagnostic tests for the detection of oral dysplasia or carcinoma. although frank malignancies are more readily diagnosed, there are inconsistencies in the categorizing and diagnosis of what are generally termed premalignant conditions. immuno- diagnosis may prove… More